• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AGN

ARGENICA THERAPEUTICS LIMITED - News & Media

1.49% ! 34.0¢
Market Cap $45.60M  !
Healthcare Biotechnology
Add to My Watchlist

Argenica Therapeutics Limited is an Australia-based biotechnology company, developing... Argenica Therapeutics Limited is an Australia-based biotechnology company, developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischemic encephalopathy (HIE). The Company has completed a Phase I clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. It has completed dosing in a Phase II clinical trial in ischaemic stroke patients and continues to generate preclinical data in other neurological conditions, including in TBI and HIE.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Argenica doses final patients in acute ischaemic stroke trial

Argenica Therapeutics Ltd has taken an important step in completion of its Phase 2 trial to test the efficacy and safety of ARG-007

11 Apr 2025 09:53 (AEST)

Argenica rat brain study shows potential neuroprotective action in ARG-007

Argenica Therapeutics's rat study of its traumatic brain injury drug ARG-007 has shown early-stage evidence of neuroprotective action.

04 Feb 2025 11:22 (AEDT)

FDA awards Argenica two key designations for drug candidate targeting infant brain injury

Argenica Therapeutics Ltd has received two key designations from the US Food and Drug Administration for its ARG-006 candidate

30 Oct 2024 14:45 (AEDT)

Argenica Therapeutics dose test raises hopes for stroke victims

Biotech firm Argenica Therapeutics has initiated dosing for the first stroke patient in its Phase 2 clinical trial of ARG007.

28 Mar 2024 12:06 (AEDT)

Argenica shares jump on key designation from US FDA for infant brain injury drug

Argenica Therapeutics announced on Monday the company has won rare pediatric disease designation (RPDD) for its flagship drug ARG-007.

25 Mar 2024 10:55 (AEDT)

Argenica Therapeutics' (ASX:AGN) study delivers "encouraging" results for ARG-007 in treating traumatic brain injury

Argenica Therapeutics (ASX:AGN) has delivered "encouraging" results from a preclinical study assessing the efficiency of ARG-007 in modTBI.

22 Jun 2023 17:06 (AEST)

Argenica Therapeutics (ASX: AGN) taps investors for $4 million to fund ischaemic stroke trial

Argenica Therapeutics (AGN) has wrapped up its $4 million placement to fund the phase two trial of its neurological drug, ARG-007.

02 Jun 2023 15:46 (AEST)

Argenica Therapeutics (ASX:AGN) confirms ARG-007 is well-tolerated in final phase one clinical report

Argenica Therapeutics (ASX:AGN) has confirmed its drug, ARG-007, is safe and well-tolerated its final phase one clinical trial report.

15 May 2023 11:01 (AEST)

Argenica Therapeutics (ASX:AGN) receives $350k cash boost to advance Alzheimers Studies

Argenica Therapeutics (ASX:AGN) has received a non-dilutive $350,000 cash boost to advance its Alzheimer's Disease studies

22 Feb 2023 12:03 (AEDT)

Argenica Therapeutics (ASX:AGN) pre-clinical data points to potential new Alzheimer's treatment

Argenica Therapeutics (ASX:AGN) has reported that pre-clinical data for its flagship ARG-007 product showed the drug inhibited one of the main causes of Alzheimer's Disease.

09 Feb 2023 12:02 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
34.0¢ 		Change
0.005(1.49%) 		Mkt cap ! $45.60M
Open High Low Value Volume
33.0¢ 35.5¢ 32.5¢ $134.1K 400.5K

Buyers (Bids)

No. Vol. Price($)
2 42029 34.0¢
 

Sellers (Offers)

Price($) Vol. No.
35.0¢ 50000 1
View Market Depth
Last trade - 10.49am 12/09/2025 (20 minute delay) ?
Last
34.0¢ 		  Change
0.005 ( 3.03 %)
Open High Low Volume
33.0¢ 35.0¢ 32.5¢ 37046
Last updated 10.54am 12/09/2025 ?
AGN (ASX) Chart

Top Stories

EVR opens strong with funding, acquisition, and sales agreement announcements

EVR has caught attention on the HotCopper forums and across the wider Australian markets today with a flurry of announcements.
Locate Technologies is ditching ASX for NZ because it wants less crypto red tape Locate Technologies is delisting from the ASX and moving to New Zealand to list on the NZX in a kind of backdoor listing.
Listen: HotCopper Wire Podcast 024 – Two '4D' stocks to watch, but only one winner In this HotCopper Wire Week 37 episode, we take a look at the Coles and Woolies legal fight and compare 4DMedical and 4DS Memory.
Mongolian gov't approves major highway intersecting Aspire Mining's Ovoot coal mine road Move over ESG. Aspire Mining, developing its Mongolian-based Ovoot Coking Coal Project (OCCP), has received a tip of partial state support.
EV Resources snaps up Nevada antimony project; will raise $5.5M for it, Los Lirios EV Resources has come out of its halt with a bang, unveiling the acquisition of the Dollar Antimony Project in Nye County alongside a raise.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.